2-吡咯烷-1-丙胺 | 50998-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-吡咯烷-1-丙胺
• 英文名称: 2-Pyrrolidin-1-yl-propylamine
• 英文别名: 2-pyrrolidin-1-ylpropan-1-amine
• CAS: 50998-07-7
• 化学式: C₇H₁₆N₂
• mdl: MFCD06446933
• 分子量: 128.217
• InChiKey: GUHQLUWDOMXRGQ-UHFFFAOYSA-N

物化性质

• 沸点：
  186.5±8.0 °C(Predicted)
• 密度：
  0.945±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-吡咯烷-1-丙胺 、 3,6-dinitro-1,8-naphthalic anhydride 以 乙醇 为溶剂， 反应 24.0h， 生成 5,8-Dinitro-2-(2-pyrrolidin-1-ylpropyl)benzo[de]isoquinoline-1,3-dione
  参考文献：
  名称：

  Brana; Castellano; Moran, Arzneimittel-Forschung/Drug Research, 1995, vol. 45, # 12, p. 1311 - 1318

  摘要：

  DOI：
• 作为产物：
  描述：

  四氢吡咯 、 2-chloropropylamine hydrochloride 在 potassium carbonate 作用下， 反应 6.0h， 以25%的产率得到2-吡咯烷-1-丙胺
  参考文献：
  名称：

  Chechik, V. O.; Bobylev, V. A., Russian Journal of General Chemistry, 1994, vol. 64, # 10.2, p. 1501 - 1502

  摘要：

  DOI：

文献信息

• [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
  申请人：INCYTE CORP

  公开号：WO2009064835A1

  公开（公告）日：2009-05-22

  The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)

  本发明提供了取代的双环杂环芳基化合物，包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺，这些化合物调节激酶的活性，在治疗与激酶活性相关的疾病方面具有用处，例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式：(1)
• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20010027193A1

  公开（公告）日：2001-10-04

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  式1中R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2烷基基团，它们的制备以及含有它们的药物组合物。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• Novel compounds useful for bradykinin B1 receptor antagonism
  申请人：Ye Michael Xiaocong

  公开号：US20070032475A1

  公开（公告）日：2007-02-08

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor.

  揭示了一种化合物，它们是布雷金肽B1受体拮抗剂，可用于治疗或缓解由布雷金肽B1受体介导的哺乳动物疾病，或与疾病状况相关的不良症状。
• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。